Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 9—September 2024
CME ACTIVITY - Research
Clinical Aspects and Disease Severity of Streptococcus dysgalactiae Subspecies equisimilis Bacteremia, Finland1
, Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
Table 5
Laboratory test results of patients with Streptococcus dysgalactiae subspecies equisimilis bacteremia in relation to nonsevere and severe disease during November 2015–November 2019, Finland*
| Laboratory test | Nonsevere disease, n = 142 | Severe disease, n = 17 | p value |
|---|---|---|---|
| Leukocyte count, × 109 cells/L | |||
| Day 0 | 16 (11–19) | 14 (11–21) | 0.973 |
| Day 1 | 13 (10–18) | 15 (11–23) | 0.370 |
| Day 2 | 11 (8–15) | 15 (10–21) | 0.032 |
| Day 3 | 10 (7–12) | 15 (10–16) | 0.020 |
| Highest† |
17 (12–21) |
19 (12–25) |
0.488 |
| C-reactive protein, mg/L | |||
| Day 0 | 70 (20–179) | 196 (21–344) | 0.093 |
| Day 1 | 177 (123–274) | 195 (94–360) | 0.439 |
| Day 2 | 207 (124–283) | 256 (120–348) | 0.329 |
| Day 3 | 149 (79–217) | 217 (124–305) | 0.030 |
| Day 4 | 99 (51–163) | 193 (100–260) | 0.009 |
| Highest‡ |
237 (163–320) |
328 (162–385) |
0.202 |
| Creatinine, µmol/L | |||
| Day 0 | 94 (78–122) | 113 (84–203) | 0.046 |
| Day 1 | 93 (81–121) | 135 (89–182) | 0.043 |
| Day 2 |
94 (73–121) |
103 (80–175) |
0.137 |
| Platelet count, × 109/L | |||
| Day 0 | 196 (159–234) | 169 (143–216) | 0.178 |
| Day 2 |
183 (146–217) |
142 (105–212) |
0.175 |
| Highest ALT,§ U/L | 26 (18–41) | 58 (25–69) | 0.052 |
*Values are median (interquartile range) except as indicated. Severe disease was defined as treatment in the intensive care unit or death within 30 days after hospital admission. ALT, alanine aminotransferase. †Highest count during days 0–3. ‡Highest level during days 0–4. §Highest level during days 0–4.
1Preliminary results from this study were presented at the European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2024; Barcelona, Spain.